Cullinan Therapeutics (CGEM) recently disclosed promising results from their Phase 1 clinical trial of CLN-049. This investigational FLT3xCD3 bispecific T cell engager is being tested on patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome. The findings will be shared at the 67th American Society of Hematology Annual Meeting and Exposition, scheduled for December 6-9, with an oral presentation on December 8 at 10:45 a.m. ET.
The data includes multiple complete responses and shows promise in terms of response durability, suggesting that CLN-049 could significantly broaden treatment avenues for AML patients, particularly those with TP53 mutations who typically have a poor prognosis. With its recent Fast Track designation by the FDA, CLN-049 is positioned as a potentially crucial new treatment option in the fight against this challenging disease, highlighting Cullinan's commitment to rapidly advancing its development.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.